By the same token, Regeneron plans to release phase II data on Trevogrumab/Garetosmab, a dual myostatin- and activin-receptor-inhibiting molecule (Table 1) [257]. In a phase 2 proof-of-concept study, Bimagrumab, an activin receptor II antibody inhibiting the actions of myostatin and ...